Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly ...

KOMMENTAR: Dele af medicinmarkedet kan tydeligvis ikke regulere sig selv med nugældende regelsæt. Danmark bør kæmpe for bedre ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

Det er magtarrogance« Novo Nordisk Fondens nye hovedkvarter får Hellerup-borgere til at vrænge på næsen: »De tromler os. Det er magtarrogance« Novo Nordisk Fondens nye hovedkvarter får ...

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has recently completed a clinical study titled ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

Fem rapporter på 15 år har vist de samme problemer med alkoholbehandlingen, men intet er sket. Behandlingen er endt i en ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Forskere har opdaget en ny effekt af vægttabsmedicin, som kan vise sig at være en meget god nyhed for en bestemt gruppe ...